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Key points
●● Nine randomised controlled trials (RCTs) on low-dose computed tomography screening were 
identified; five were included for meta-analysis but only two of those were at low risk of bias.
●● In a meta-analysis of recent low risk of bias RCTs including 8156 healthy current or former smokers 
from developed countries, we found that 49% of the screen-detected cancers may be overdiagnosed.
●● There is uncertainty about the degree of overdiagnosis in lung cancer screening due to unexplained 
heterogeneity and low precision of the point estimate.
●● If only high-quality RCTs are included in the meta-analysis, the degree of overdiagnosis is substantial.
Educational aims
●● To appreciate that low-dose computed tomography screening for lung cancer meets all three 
main conditions for overdiagnosis in cancer screening: a reservoir of indolent cancers exists 
in the population; the screening test is able to “tap” this reservoir by detecting biologically 
indolent cancers as well as biologically important cancers; and the population being screened is 
characterised by a relatively high competing risk of death from other causes
●● To learn about biases that might affect the estimates of overdiagnosis in randomised controlled 
trials in cancer screening
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In low-dose computed tomography (LDCT) screening for lung cancer, all three main reasons for 
overdiagnosis are present. Half of people detected as having lung cancer via their participation in 
LDCT screening are overdiagnosed. http://bit.ly/32tLZk4
In low-dose computed tomography (LDCT) screening for lung cancer, all three main conditions for 
overdiagnosis in cancer screening are present: 1) a reservoir of slowly or nongrowing lung cancer 
exists; 2) LDCT is a high-resolution imaging technology with the potential to identify this reservoir; 
and 3) eligible screening participants have a high risk of dying from causes other than lung cancer. 
The degree of overdiagnosis in cancer screening is most validly estimated in high-quality randomised 
controlled trials (RCTs), with enough follow-up time after the end of screening to avoid lead-time 
bias and without contamination of the control group.
Nine RCTs investigating LDCT screening were identified. Two RCTs were excluded because 
lung cancer incidence after the end of screening was not published. Two other RCTs using 
active comparators were also excluded. Therefore, five RCTs were included: two trials were at 
low risk of bias, two of some concern and one at high risk of bias. In a meta-analysis of the two 
low risk of bias RCTs including 8156 healthy current or former smokers, 49% of the screen-
detected cancers were overdiagnosed. There is uncertainty about this substantial degree of 
overdiagnosis due to unexplained heterogeneity and low precision of the summed estimate 
across the two trials.
Review
Overdiagnosis of lung cancer with 
low-dose computed tomography 
screening: meta-analysis of 
the randomised clinical trials
Broadly, overdiagnosis means making people patients 
unnecessarily, by identifying problems that were 
never going to cause harm or by [over]medicalising 
ordinary life experiences through expanded definitions 
of diseases.
Brodersen et al. [1]
Overdiagnosis has two major causes: overdetection 
and overdefinition. In cancer screening, it is 
overdetection that is in play and it refers to 
identification of indolent cancer pathology: pathology 
that will never cause harm, never progress, 
progress too slowly to cause symptoms or harm 
during a person’s remaining lifetime, or that 
resolves spontaneously [2]. Many countries are 
currently considering the introduction of low-dose 
computed tomography (LDCT) screening for lung 
cancer in high-risk groups. Good policy decisions 
about screening are informed by the best available 
evidence concerning the benefits, harms, costs and 
ethical implications of screening for individuals 
and for society. In this regard, the extent of 
overdiagnosis due to lung cancer screening requires 
attention as it is the most severe potential harm 
of screening and because LDCT screening for lung 
John Brodersen 1,2, Theis Voss 1,2, Frederik Martiny 1,2, Volkert Siersma 1, Alexandra Barratt 3, 
Bruno  Heleno 4
jobr@sund.ku.dk
Cite as: Brodersen J, Voss T, 
Martiny F, et al. Overdiagnosis 
of lung cancer with low-dose 
computed tomography 
screening: meta-analysis of 
the randomised clinical trials. 
Breathe 2020; 16: 200013.
3 Breathe | March 2020 | Volume 16 | No 1
Overdiagnosis of lung cancer with low-dose CT screening
cancer demonstrates all three main conditions for 
overdiagnosis due to overdetection [2, 3]:
●● there is empirical evidence of substantial 
heterogeneity in growth rates of LDCT screening-
detected lung cancers, indicating that a reservoir 
of slowly or nongrowing lung cancer exists [4–6].
●● current and former heavy smokers have a 
high risk of dying from causes other than 
lung cancer; for example, from cardiovascular 
diseases.
●● LDCT scans have a much higher resolution than 
chest radiography, thus increasing its ability to 
detect the reservoir of indolent/slow-growing 
pathology.
Screening with chest radiography has previously 
been shown to result in overdiagnosis of lung cancer 
[7]. Therefore, LDCT screening for lung cancer will 
inevitably result in some degree of overdiagnosis. 
Because LDCT can detect smaller cancers than can 
chest radiography, CT scanning would be expected 
to find more cancers, and the absolute number 
of both biologically important and of biologically 
indolent cancers will be increased. Furthermore, 
if even smaller lung cancer nodules have even 
slower growth rates than the bigger nodules – or 
no growth at all – then the degree of overdiagnosis 
in CT screening would theoretically be expected to 
be greater compared to the degree of overdiagnosis 
in chest radiography [2].
Overdiagnosis may result in all the harms of 
regular diagnosis, from which it is indiscernible, 
but, by definition, without providing any benefits. 
Harms range from physical harm from unnecessary 
diagnostic tests and treatments; to psychosocial 
harm when people are told that they have a 
fatal disease; to economic harm, such as loss of 
income while undergoing tests and treatment; 
to opportunity costs, such as time that could be 
otherwise spent with loved ones; and finally, to 
societal costs, since the resources used in screening 
and downstream procedures could be used in other 
healthcare activities [8]. Moreover, overdiagnosis 
occurs to a greater or lesser extent in screening 
programmes that target the actual cancer and 
not its precursors [9]. So, to balance the potential 
intended benefits and the inevitable unintended 
harms of cancer screening, an assessment of 
overdiagnosis is needed [10, 11].
Overdiagnosis is, together with false positives 
and a general increased fear in society, an important 
driver of harms of screening [12–14]; thus, it should 
be reported in every trial assessing screening. The 
degree of overdiagnosis in cancer screening is most 
validly estimated in high-quality randomised trials 
with enough follow-up time to avoid lead-time bias 
and with no contamination of the control group 
[3, 15]. Lead time is the length of time between 
screen-detected lung cancer and the theoretical 
time point of the clinical presentation of lung cancer 
in a setting with no screening. In the present paper, 
sufficient follow-up time to avoid lead-time bias 
is 3.6 years [16]. Contamination is defined as the 
proportion of the control group who have been 
screened; the higher the contamination rate, 
the more the estimate of overdiagnosis is biased 
towards the null.
For example, the US National Lung Cancer 
Screening Trial (NLST) compared three rounds of 
screening with LDCT (n=26 722) to three rounds of 
screening with chest radiography (n=26 730) [17]. 
After a mean follow-up time of 6.4 years, 18.5% of 
the screen-detected cancers were estimated to be 
overdiagnosed [18]. The follow-up time is enough 
to account for the lead-time, i.e. to ensure that all 
cancer that would have presented clinically have 
been diagnosed in the control group. However, as 
screening with chest radiography has also been 
shown to result in overdiagnosis of lung cancer [7], 
the control group is contaminated and the degree of 
overdiagnosis for LDCT screening is underestimated 
in the NLST.
In view of the contamination due to using active 
comparators in screening trials, the aim of this 
study was to estimate the degree of lung cancer 
overdiagnosis due to LSCT screening compared with 
no screening. To provide the best quality evidence, 
we performed a meta-analysis of randomised 
controlled trials (RCTs) only.
Methods
Eligibility criteria
Randomised trials were eligible if they reported the 
incidence of lung cancer for people screened with 
LDCT compared to people who were not screened 
(usual care).
Randomised trials were excluded if:
●● they did not provide long-term cumulative lung 
cancer incidence during follow-up, i.e. after the 
active phase of trials; or
●● the control group was offered any type of lung 
cancer screening after or during the RCT.
In all but one trial, screening participants were 
at high risk of lung cancer due to being either 
former or current smokers with a history of ≥20 
pack-years. In the Chinese Yang trial, participants 
were also eligible if they had a family or personal 
cancer history, occupational exposure, second-
hand smoking or long-term exposure to cooking 
oil fumes. We included trials regardless of risk of 
bias. There were no restrictions concerning date 
of publication or language.
Search strategy
We searched PubMed for reviews of lung cancer 
screening with LDCT using the search terms 
“screening”, “low-dose computed tomography” and 
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“lung cancer”, or the name of the trials we knew 
of that had evaluated or are evaluating lung cancer 
screening with LDCT, in the title, abstract or keywords 
of publications. We extracted the references to lung 
cancer screening trials included in these reviews. 
From our >15 years of research in the Danish Lung 
Cancer Screening Trial (DLCST), we knew of eight 
RCTs comparing LDCT to no screening [19]:
●● Chinese Yang Trial
●● DLCST [20]
●● German Lung Cancer Screening Intervention 
Study (LUSI) [21]
●● Multi-Centric Italian Lung Detection Trial 
(MILD) [22]
●● Italian Lung Cancer Computed Tomography 
Screening Trial (ITALUNG) [23]
●● Detection and Screening of Early Lung Cancer by 
Novel Imaging Technology and Molecular Assays 
(DANTE) [24]
●● Nederlands-Leuvens Longkanker Screenings 
Onderzoek (NELSON) [25]
●● UK Lung Cancer Screening trial (UKLS) [26]
One more RCT on LDCT screening we knew of 
was the American NLST [17], which compared 
LDCT to chest radiography. The NLST was not 
included in the present review due to the active 
comparator.
Data collection and extraction
Selection of studies
If any of the eight trials were reported in multiple 
articles, we selected the article reporting the longest 
follow-up time.
Data extraction and management
Two authors (T. Voss and B. Heleno) independently 
extracted data from the included trials and entered 
them into a data extraction form in Excel (Microsoft 
Corp., Redmond, WA, USA). Disagreements were 
resolved through discussion with a third review 
author.
We extracted the following data:
●● Inclusion and exclusion criteria for the study 
population
●● Characteristics of participants (sex, age and 
number enrolled in each group)
●● Number of screening rounds and interval 
between screening rounds
●● Characteristics of any comparator screening 
intervention
●● Definition of an abnormal screening result
●● The incidence of cancer in the screened group 
and in the control group
●● Number or proportion of screen-detected 
cancers in the screened group
●● The participation rate (participation defined as 
having had at least one screening test)
●● The contamination rate (number in the control 
group with at least one screening test during the 
active phase or during follow-up)
●● The rate of screening in both arms of the trial 
after the active phase
●● The duration of follow-up
Assessment of risk of bias
The Cochrane Risk of Bias tool
Two authors (T. Voss and B. Heleno) independently 
assessed the risk of bias of the included RCTs using 
the Cochrane Collaboration’s Risk of Bias tool 2.0 
[27], which includes the following domains.
●● Risk of bias arising from the randomisation 
process.
●● Risk of bias due to deviations from intended 
interventions. Contamination bias was assessed 
under this dimension.
●● Risk of bias due to missing outcome data.
●● Risk of bias due to measurement of the 
outcome. Lead time bias was assessed under this 
dimension. As mentioned in the introduction, 
we considered that trials adequately accounted 
for lead-time when follow-up since the last 
screening round was >3.6 years [16].
●● Risk of bias due to selection of the reported result.
●● Overall risk of bias assessment.
Data management and 
statistical analysis
To estimate the degree of overdiagnosis, we 
calculated the risk ratio (RR) of lung cancer and 
the respective 95% confidence intervals. The 
RR expresses the increase or the decrease in the 
incidence of lung cancer at the population level if 
LDCT screening for lung cancer screening was to be 
implemented. If the lung cancer incidence in the 
screened group and the lung cancer incidence in 
the control group are the same, with a sufficiently 
long follow-up time, then there is no overdiagnosis. 
If the lung cancer incidence in the screened group is 
greater than the lung cancer incidence in the control 
group, again with a sufficiently long follow-up time, 
this is evidence of overdiagnosis. And finally, if 
the lung cancer incidence in the screened group 
is smaller than the lung cancer incidence in 
the control group, also under the condition of a 
sufficiently long follow-up time, then the screening 
prevents cancers from occurring (the screening has 
a primary preventive effect).
We also calculated another measure of 
overdiagnosis that has been used in several previous 
studies and thereby can be used for comparisons 
representing the risk that a screen-detected cancer 
is overdiagnosed. This standard measure is more 
informative when an individual eligible screening 
participant is to be informed about pros and cons of 
screening, i.e. what is the likelihood that the cancer 
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is overdiagnosed should you be detected with a 
cancer in the screening programme [3, 28]:
Cumulative cancer incidence in the
screenedpopulation
Number of subjects screened
Cumulative cancer incidence in the⎛
⎝
⎜⎜⎜⎜
⎞
⎠
⎟⎟⎟⎟
−
controlpopulation
Number of control subjects
Cumul
⎛
⎝
⎜⎜⎜⎜
⎞
⎠
⎟⎟⎟⎟
ativenumber of screen
-detectedcancers
Number of subjects screened
⎛
⎝
⎜⎜⎜⎜
⎞
⎠
⎟⎟⎟⎟
×100
The risk that a screen-detected cancer is 
overdiagnosed is more sensitive to the baseline 
incidence of cancer diagnosis compared to the RR 
of cancer. Therefore, we calculated both measures. 
The cumulative cancer incidence in the screened 
population was defined as all cancers detected in 
the population offered screening during and after 
the active phase. Likewise, the cumulative cancer 
incidence in the control population was defined 
as all cancers detected in the control population 
during and after the active phase. The cumulative 
number of screen-detected cancers was defined as 
all cancers detected by screening in the population 
offered screening during the active phase.
Using R (The R Foundation, Vienna, Austria), 
we calculated standard deviations of this measure 
through bootstrapping and used a normal 
approximation to compute 95% confidence intervals.
We assumed that the baseline risk of lung 
cancer in the absence of screening was the median 
incidence of lung cancer in the control arms of the 
included trials.
Data synthesis
We pooled overdiagnosis estimates across included 
RCTs. Results were summarised with a random-
effects meta-analysis using the inverse-variance 
method, as we anticipated some variation due to the 
different timing, follow-up and settings of individual 
trials. Data were analysed using Review Manager 
version 5.3 (The Nordic Cochrane Collaboration, 
Copenhagen, Denmark).
Sensitivity analysis
We performed a secondary meta-analysis restricted 
to trials with low risk of bias across all domains.
Results
In our literature search, we identified the nine trials 
investigating LDCT screening, of which we already 
knew (table S1) [17, 23–26, 29–32]. This paper 
was first submitted to the journal Breathe on 20 
January 2020. On 29 January 2020, the NELSON 
trial published its results [33], and we included the 
NELSON trial’s results in a revised version of the 
manuscript. Therefore, five trials were included in 
the present study: DLCST, ITALUNG, LUSI, MILD and 
NELSON (table 1) [23, 29–31, 33]. Two trials (UKLS 
and the Chinese Yang trial) were not included since 
no data on the incidence after the end of screening 
in these two trials were published [26, 32]. Two 
trials used active comparators and therefore were 
not included: the NLST compared LDCT screening 
with chest radiography and DANTE offered a single 
baseline chest radiography screening to the control 
group [17, 24].
The main characteristics of each trial and our risk 
of bias rating are summarised in table 1. The median 
cumulative risk of lung cancer in the control groups 
was 3.96% during the active screening phase in the 
intervention groups across the five trials. Two of 
the included trials (DLCST and LUSI), accounting for 
21.6% of the lung cancers, were at low risk of bias 
[29, 30]. There were some concerns regarding the 
ITALUNG trial, since the extent of contamination in 
the control group was not reported [23]. The MILD 
trial was at high risk of bias because of baseline 
differences (89% current smokers in control 
group versus 68.3%/68.8% in intervention group, 
and it only started randomising participants to an 
unscreened control group 6 months after it started 
randomising participants). Recent results from 
the NELSON trial focus on men even though the 
protocol of the NELSON trial and earlier publications 
suggest that data about men and women would be 
reported in the same analyses [25]. Moreover, data 
about contamination in the NELSON is restricted 
to the baseline round [34].
Main analysis
We found that LDCT screening of former or current 
smokers increases the cumulative incidence of lung 
cancer (RR 1.22) with a 95% confidence interval 
of 1.02–1.47 and heterogeneity (I2) 55% (figure 1). 
Of the screen-detected cancers, we estimate that 
38% (95% CI 14%–63%) may be overdiagnosed 
(I2=65%) (figure 2).
Sensitivity analysis
Findings from the sensitivity analysis restricted to 
the two trials at low risk of bias in all dimensions 
suggests a larger RR point estimate (1.51, 95% CI 
1.06–2.14; I2=58%) (figure 3) and similar probability 
that a screen-detected cancer is overdiagnosed 
(49%, 95% CI 11%–87%) (figure 4).
Discussion
Summary of main findings
Using data from the latest publications of low risk 
of bias trials comparing screening by LDCT with 
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usual care, we found that screening annually five 
times with 3–5 years of follow-up increased the 
cumulative incidence of lung cancer (1.51, 95% 
CI 1.06–2.14). This corresponds to statistically 
significant absolute risk increase of 20 cancers per 
1000 people screened, assuming a median baseline 
risk in the control group of 40 lung cancers per 
1000 participants. We estimated that 49% (95% 
CI 11–87%) of the LDCT screen-detected cancers 
may be overdiagnosed. Using data from all included 
trials, regardless of the risk of bias, we found an 
increased cumulative incidence of lung cancer (RR 
1.22, 95% CI 1.02–1.47), which corresponds to 
an absolute risk increase of nine cancers per 1000 
people screened. Here, we estimated that 38% 
(95% CI 14–63%) of the LDCT screen-detected 
cancers may be overdiagnosed.
Strengths and weaknesses
We used prior reviews of lung cancer screening to 
identify trials of LDCT screening and selected those 
that had an unscreened control group with published 
data on long-term cumulative lung cancer incidence. 
One potential weakness of our approach is that our 
meta-analysis is based on a rapid review, which might 
lead to unintentional omission of important trials and/
or publications. However, we consider it unlikely that 
we have missed important trials and/or publications 
concerning LDCT screening for lung cancer due to 
our commitment to this field for >15 years. Similar 
to systematic reviews, we have extracted key data 
from all included trials, presented in table 1, and we 
have performed a thorough risk of bias assessment of 
included trials, independently by two review authors. 
Therefore, we believe that we have accounted for key 
differences between included trials.
The quality of the primary studies included 
in the meta-analysis was moderate. Two trials 
(DLCST and LUSI), accounting for around 22% of 
the lung cancers included in the meta-analysis, 
were at low risk of bias. The major threats to 
the confidence in our estimates are the high, 
unexplained heterogeneity between all five included 
trials (I2=55%) and the imprecision of the pooled 
estimate (the confidence interval for the meta-
analysis spans 1.02–1.47). The heterogeneity was 
still high (I2=58%) in our sensitivity analysis of low 
risk of bias trials and consequently, the precision 
was low (1.06–2.14).
If we assume a baseline risk of 40 lung cancers 
per 1000 participants (corresponding to the 2.58% 
median cumulative risk of lung cancer in the control 
groups across included trials), our results in the low 
risk of bias trials are compatible with an absolute 
risk increase between two cancers per 1000 (based 
on the lower bound of the confidence interval of 
1.06) and 46 per 1000 participants screened (based 
on the upper bound of the confidence interval of 
2.14). If all trials are included in the analysis, the 
results would between an absolute risk increase of 
one per 1000 to 19 per 1000 participants.
There is an additional concern when interpreting 
our results of overdiagnosis. In cancer screening trials, 
persistent excess cancers in the screening arm is seen 
as evidence of overdiagnosis. For this to be true, the 
follow-up since the last screening round needs to 
be longer than the lead time, i.e. the average length 
Heterogeneity: τ2=0.02; χ2=8.89, df=4 (p=0.06), I2=55%
Test for overall eect: z=2.13 (p=0.03)
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Figure 1 Forest plot of the RR of the cumulative incidence of lung cancer (estimates >1 represent overdiagnosis). The meta-analysis includes all trials, regard-
less of bias assessment. Trials are listed alphabetically. M-H: Mantel-Haenszel; df: degrees of freedom.
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of time the diagnosis of a cancer is brought forward 
through screening [35]. The LUSI trial included in the 
meta-analysis has <3.6 years of follow-up since the 
last screening round [30]. In addition, the follow-up 
time in the MILD trial is unclear due to nonreporting 
of the screening-free interval for participants in both 
the protocol and in publications [31, 36, 37]. Thus, 
it is possible that our current pooled estimate of the 
number of excess cancers in the screened group is 
affected by unaccounted lead time. If that is true, our 
results could overestimate the extent of overdiagnosis 
in lung cancer screening. Conversely, contamination 
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Figure 3 Forest plot of the RR of the cumulative incidence of lung cancer (estimates >1 represent overdiagnosis). The meta-analysis only includes low risk of 
bias trials. Trials are listed alphabetically. M-H: Mantel-Haenszel; df: degrees of freedom.
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Figure 2 Forest plot of estimates of overdiagnosis defined as the fraction of screen-detected lung cancers that represent overdiagnosis. Meta-analysis includes 
all trials, regardless of bias assessment. Trials are listed alphabetically. IV: inverse variance; df: degrees of freedom.
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of the control group would bias the estimate of 
overdiagnosis towards the null. Contamination of 
the control group was 11.4% in the LUSI trial and 
1.2% in the MILD trial [22, 30]. Contamination was 
assessed using a questionnaire in the LUSI trial and, 
judging from the publication by phone calls, e-mail 
and contacts with general practitioners or referring 
hospitals in the MILD trial [22, 30]. The contamination 
rate is likely underreported in both LUSI and MILD 
because the methods used to estimate contamination 
rates in these two trials are not as valid the high-quality 
registries used in the DLCST, where contamination of 
the control group was 20.3% [29, 38].
Interpretation of the results in 
the context of previous literature
Other estimates of the effect of screening on 
long-term cancer incidence
The NLST, the previously mentioned, large US trial 
comparing screening for lung cancer with LDCT 
scans against screening with chest radiography, also 
found evidence of overdiagnosis [18]. They reported 
an 18.5% probability (95% CI 5.4%–30.6%) that 
any lung cancer detected by screening with LDCT 
was an overdiagnosis. In an 11.3-year follow-up of 
the NLST, this 18.5% probability of overdiagnosis 
had decreased to 0%. Whether this is due to an 
actual compensatory drop in the incident lung 
cancer rate or whether this is due to contamination 
of the control – or both – is uncertain [39]. The 
degree of contamination is not reported in the 
11.3-year follow-up that went to the end of 2014 
[39]. In 1996, the US Preventive Service Task Force 
(USPSTF) recommended against screening for lung 
cancer [40]. In 2004, the task force recommended 
neither for nor against [40], while in 2013, the 
USPSTF recommended annual screening with 
LDCT for lung cancer in people who had a smoking 
history of 30 pack-years and were aged 55–80 years 
[41]. The timing between the different USPSTF 
recommendations and the drop in the overdiagnosis 
estimate raises concern that contamination of the 
control group is most likely a part of the explanation. 
In support of this hypothesis, a theoretical lead-
time of 3.6 years for lung cancer should lead to a 
compensatory drop in the incident lung cancer rate 
occurring sooner than after an 11.3-year follow-up.
Researchers from the NLST also used a 
convolution model to address two limitations of their 
study (the active comparator and the short follow-up 
period). They estimated that 11% of the screen-
detected cancers could be due to overdiagnosis after 
accounting for model-based lead time [18]. Another 
modelling study estimated that overdiagnosis 
relative to no screening would be 10–12% of the 
screen-detected cancers across a wide range of 
simulated lung cancer screening programmes [42]. 
Of note, a systematic review found that no modelling 
studies on overdiagnosis in cancer screening relied 
on systematically reviewed evidence. In addition, 
the modelling studies did not validate their models 
using datasets from populations who were different 
from those in which the models were developed 
and calibrated. Finally, the included populations 
were different from those in which the models were 
calibrated. All this should cause doubt about the 
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Figure 4 Forest plot of estimates of overdiagnosis defined as the fraction of screen-detected lung cancers that represent overdiagnosis. The meta-analysis only 
includes low risk of bias trials. Trials are listed alphabetically. IV: inverse variance; df: degrees of freedom.
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validity of the findings from modelling studies on 
overdiagnosis in cancer screening [15].
Best estimates of the benefit of screening
A recent systematic review found that LDCT scan 
screening reduced lung cancer mortality (RR 0.83, 
95% CI 0.76–0.90) [43]. This corresponds to an 
absolute risk reduction of seven lung cancer deaths 
per 1000 people screened, assuming a median 
baseline risk in the control group of 33 lung cancer 
deaths per 1000 participants. The systematic review 
did not find a significant effect on all-cause mortality 
(RR 0.95, 95% CI 0.90–1.00) [43]. Assuming the 
lung cancer mortality reduction is correct and 
assuming a median baseline risk in the control 
group of 114 overall deaths per 1000 participants, 
this corresponds to an absolute risk reduction of 
four deaths due to any cause per 1000 participants.
Clinical implications
Overdiagnosis is one of the most serious adverse 
effects of screening. In people with similar 
characteristics to those included in the European 
trials, we currently estimate an increase of 20 
cancers per 1000 participants screened with LDCT 
scans. Based on recent systematic reviews, we 
expect that screening would prevent seven lung 
cancer deaths per 1000 participants, giving a ratio 
of approximately three overdiagnosed lung cancers 
per lung cancer death averted by LDCT screening. 
Besides this information, it should be communicated 
to eligible LDCT screening participants that there is a 
risk of a false-positive screening result. The average 
false-positive rate per screening round varies hugely 
in the RCTs: 23% in the NLST [17] and 3% in the 
DLCST [44], while in an ongoing LDCT screening 
programme, the false-positive rate might be as high 
as nearly 60% [45]. Moreover, there is evidence from 
all the European trials that LDCT screening for lung 
cancer does not reduce overall mortality.
There are two ongoing trials of screening for lung 
cancer with LDCT scans that have not published 
their final results: UKLS (4055 participants) [26] 
and the Chinese trial (6717 participants) [32]. It 
is possible that the estimate of overdiagnosis will 
change with the publication of these trials, and with 
the availability of more mature data from the LUSI 
and MILD trials [22, 30].
Implications for research
Lung cancer screening leads to a reduction in 
mortality while it also leads to additional harm 
due to overdiagnosis and a high number of false 
positives. Decision makers face a difficult situation 
trying to balance the benefits and harms of lung 
cancer screening: firstly, because the decision 
whether “benefit outweighs harms” is value 
laden, and likely varies between individuals and 
across cultural settings; and secondly, because 
tools to assist decision makers with balancing the 
benefits and harms of screening are sparse [45, 46]. 
Moreover, the balance between benefits and harms 
of LDCT lung cancer screening should be viewed 
with its direct and indirect costs to individuals and 
society compared to public health alternatives such 
as primary tobacco prevention. Researchers need to 
assess potential ways to minimise harms of LDCT 
screening, especially the degree of overdiagnosis. The 
source of the variation in lung cancer overdiagnosis 
rates is currently unknown but should be the focus of 
future research to better understand what causes it 
and how to prevent it if lung screening programmes 
are implemented. Sources of possible variation that 
could be investigated include:
●● variation in the population screened (age group 
screened, definition of heavy smokers and 
other risks specific to the screened population 
including, e.g. asbestos and genomic variability)
●● differences in screening practice (screening 
intervals, numbers of screening rounds, differences 
in screening technology and differences in how 
abnormal findings are managed)
●● professional differences (radiological and 
pathological thresholds)
A first potential strategy to reduce overdiagnosis 
is changing the eligibility criteria for LDCT screening. 
To date, participants have been selected based 
on age and smoking history. Now, there are risk 
prediction models that consider other variables, 
and may be better at increasing the benefits and 
decreasing the harms of LDCT screening. However, 
high-quality RCTs are needed to give valid answers 
to such research questions. The second strategy is 
changing the frequency of screening, the criteria 
for recall to further investigation, and thresholds 
to start or to stop screening. Modelling studies are 
exploring the consequences of changing screening 
parameters. Again, high quality evidence from RCTs 
is needed. Given the trade-offs between benefits 
and harms, researchers need to consider how 
decision aids may be incorporated into screening 
programmes to help healthy heavy smokers (current 
and former) make an informed choice about whether 
to participate in CT screening for lung cancer.
Self-evaluation questions
1. What are the three main reasons that lead to overdiagnosis in cancer 
imaging screening?
2. Besides the usual biases that are supposed to be assessed in 
randomised controlled trials, which two additional biases are 
of importance when estimating the degree of overdiagnosis in 
randomised controlled cancer screening trials?
3. What is the extent of overdiagnosis in lung cancer screening with 
low-dose computed tomography scans?
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Conclusion
We found that screening increases the long-term, 
cumulative incidence of lung cancer (1.51, 95% 
CI 1.06–2.14) and that 49% of screen-detected 
cancers may be overdiagnosed (95% CI 11%–
87%). This corresponds to an absolute risk 
increase of 20 cancers per 1000 people screened 
(range 2–46 per 1000 screened), assuming a 
median baseline risk in the control group of 40 
lung cancers per 1000 participants. However, 
there is great uncertainty about the degree of 
overdiagnosis in lung cancer screening due to the 
heterogeneity of all included trials, imprecision 
of the point estimate and large variation in the 
quality of the included trials.
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